About this Research Topic
The treatment landscape of solid tumors and hematologic malignancies have dramatically improved over the last decades with the advent of immunotherapy such as immune checkpoint inhibitors for solid tumors and lymphomas, adoptive T-cell therapy such as chimeric antigen receptor T-cell for hematologic malignancies as well as bispecific antibodies. Antibody-drug conjugates (ADC) are an important component of this revolution with more than 100 drugs under clinical development. Several ADCs has been already approved in breast cancer, gynaecological malignancies, urothelial carcinomas as well as haematological malignancies.
The mechanism of action of ADCs remains unclear and the clinical efficacy is counterbalanced by the emergence of acquired resistance. The mechanisms of resistance are not also depicted. Moreover, the interaction of this new category of drugs with the tumor microenvironment is not well known to date. Moreover, the role of combination strategies of ADCs with other agents such as immune checkpoint inhibitors, tyrosine kinase inhibitors and other ADCs is under clinical evaluation.
The scope of this Research Topic is to discuss the mechanism of action of multiple ADCs approved or under clinical development as well as the mechanism of resistance to these agents and potentially explore the interaction of ADCs with tumor microenvironment and the predictive factors of response to ADCs. We are also interested in the combination strategies with ADCs. Original articles and review articles are welcomed.
The mechanism of action of ADCs remains unclear and the clinical efficacy is counterbalanced by the emergence of acquired resistance. The mechanisms of resistance are not also depicted. Moreover, the interaction of this new category of drugs with the tumor microenvironment is not well known to date. Moreover, the role of combination strategies of ADCs with other agents such as immune checkpoint inhibitors, tyrosine kinase inhibitors and other ADCs is under clinical evaluation.
The scope of this Research Topic is to discuss the mechanism of action of multiple ADCs approved or under clinical development as well as the mechanism of resistance to these agents and potentially explore the interaction of ADCs with tumor microenvironment and the predictive factors of response to ADCs. We are also interested in the combination strategies with ADCs. Original articles and review articles are welcomed.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
